Experienced in RASopathies

Dr. Lyndon J. Kim

Neurosurgery | Oncology | Hematology Oncology
Icahn School Of Medicine At Mount Sinai
1 Gustave Levy Place, Mount Sinai Emergency Room, 
New York, NY 
Offers Telehealth
Experienced in RASopathies
Icahn School Of Medicine At Mount Sinai
1 Gustave Levy Place, Mount Sinai Emergency Room, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lyndon Kim is a Neurosurgery specialist and an Oncologist in New York, New York. Dr. Kim is rated as an Experienced provider by MediFind in the treatment of RASopathies. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Oncology
Hematology Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Mount Sinai Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
1 Gustave Levy Place, Mount Sinai Emergency Room, New York, NY 10029

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 1
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

33 Total Publications

Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group.
Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group.
Journal: Cancers
Published: June 27, 2024
Similar Doctors
Experienced in RASopathies
Dr. Joshua B. Bederson
Neurosurgery
Experienced in RASopathies
Dr. Joshua B. Bederson
Neurosurgery

Icahn School Of Medicine At Mount Sinai

1010 N Broadway, 
Yonkers, NY 
 (12.9 miles away)
212-731-6761
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Bederson is a Neurosurgery provider in Yonkers, New York. Dr. Bederson is rated as a Distinguished provider by MediFind in the treatment of RASopathies. His top areas of expertise are Meningioma, Pituitary Tumor, Hypothalamic Tumor, Balloon Sinuplasty, and Thrombectomy.

Experienced in RASopathies
Dr. Etta B. Frankel
Hematology Oncology | Oncology
Experienced in RASopathies
Dr. Etta B. Frankel
Hematology Oncology | Oncology

Icahn School Of Medicine At Mount Sinai

1000 10th Ave, 
New York, NY 
 (2.2 miles away)
212-523-5559
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Etta Frankel is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Frankel is rated as an Advanced provider by MediFind in the treatment of RASopathies. Her top areas of expertise are Essential Thrombocythemia, Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, and Thalassemia.

Experienced in RASopathies
Dr. Mohamad A. Cherry
Hematology Oncology | Hematology | Oncology
Experienced in RASopathies
Dr. Mohamad A. Cherry
Hematology Oncology | Hematology | Oncology

Practice Associates Medical Group

100 Madison Ave, 
Morristown, NJ 
 (26.8 miles away)
973-971-5596
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohamad Cherry is a Hematologist Oncology specialist and a Hematologist in Morristown, New Jersey. Dr. Cherry is rated as a Distinguished provider by MediFind in the treatment of RASopathies. His top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, Midline Lethal Granuloma, and Bone Marrow Aspiration. Dr. Cherry is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kim's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 8 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile